FOYA recognizes innovation and excellence in pharmaceutical manufacturing in a variety of categories and traditionally announces the Overall Winner in October. The Overall FOYA Winner was announced at the 2025 ISPE Annual Meeting & Expo during the ISPE FOYA Banquet and Awards Celebration, which took place in Charlotte, NC, US, on 26 October 2025. The celebration brought together 2025 FOYA category winners, along with service providers, partners, and industry professionals for an evening of connection, recognition, and inspiring dialogue around innovation in pharmaceutical manufacturing. The event served as a culmination event for the 2025 FOYA program and commemorated FOYA’s 20th anniversary.
“As FOYA marks its 20th anniversary, we are pleased to recognize CSL Behring’s project that truly exemplifies the spirit of the FOYA program—where innovation, impact, and excellence converge to shape the future of pharmaceutical manufacturing,” said Mike Martin, ISPE President and CEO. “CSL Behring’s Project Aurora is more than a technical achievement; it’s a bold vision brought to life. From advanced automation and robotics to sustainable design and end-to-end scalability, this facility sets a new benchmark for what Pharma 4.0™ integration can achieve. It’s a blueprint for the future of bi-omanufacturing.”
CSL Project Aurora is a significant base fractionation expansion initiative at the Broadmeadows Campus in Victoria, Australia. The project has enabled end-to-end manufacturing at the site by supplying intermediate products, from plasma to CSL’s existing immunoglobulin and albumin facilities. CSL has incorporated a full-scale application and integration of various robotics and automation technologies into this project. This ultimately increases the capacity of CSL’s largest site to nine times its previous level and achieves the plasma processing capacity equivalent of over 10 million liters of plasma per year.
From advanced automation and robotics to sustainable design and end-to-end scalability, this facility sets a new benchmark for what Pharma 4.0™ integration can achieve. It’s a blueprint for the future of biomanufacturing.
Prior to its Overall FOYA Winner recognition, CSL Behring’s Project Aurora was announced as a 2025 ISPE FOYA submission finalist at the 2025 ISPE Facilities of the Future Conference and as the 2025 ISPE FOYA category winner for Pharma 4.0™ at the 2025 ISPE Europe Annual Conference.
About ISPE’s FOYA
Since 2005, ISPE’s FOYA has recognized state-of-the-art projects using new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery.
Each year, submissions are accepted from projects worldwide, representing breakthroughs in various disciplines, from automation and integration to the development of medicines for underserved populations. Ultimately, a panel of industry leaders chooses the projects that set the standard to receive FOYA in the following categories:
- Innovation
- Operations
- Supply Chain
- Pharma 4.0™
- Social Impact
Learn more about FOYA
